scientific-skills/clinical-reports/references/regulatory_compliance.md
HIPAA Privacy Rule protects individually identifiable health information (Protected Health Information, PHI). All clinical reports must comply with HIPAA requirements for privacy and security.
Definition: Individually identifiable health information held or transmitted by covered entities or business associates in any form or medium.
Covered Entities:
Business Associates:
These identifiers must be removed for Safe Harbor de-identification:
Remove all 18 identifiers AND have no actual knowledge that remaining information could be used to identify the individual.
Implementation:
Statistical/scientific analysis demonstrating that risk of re-identification is very small.
Requirements:
Principle: Use, disclose, and request only the minimum PHI necessary to accomplish purpose.
Exceptions:
Implementation:
When required:
Required elements of authorization:
Administrative Safeguards:
Physical Safeguards:
Technical Safeguards:
Breach definition: Unauthorized acquisition, access, use, or disclosure of PHI that compromises security or privacy.
Notification requirements:
Content of notification:
Civil penalties (per violation):
Criminal penalties:
HIPAA authorization for research:
Waiver of authorization:
Limited data sets:
FDA regulation establishing criteria for electronic records and electronic signatures to be considered trustworthy, reliable, and equivalent to paper records.
Applies to:
System validation:
Audit trails:
Operational checks:
Record retention:
General requirements:
Components:
Controls:
Electronic signature manifestations: Must include:
Closed system:
Open system:
Requirements:
Grandfather clause:
International ethical and scientific quality standard for designing, conducting, recording, and reporting trials involving human subjects.
Purpose:
Regulatory adoption:
1. Ethics: Clinical trials should be conducted in accordance with ethical principles (Declaration of Helsinki, local laws)
2. Risk-benefit: Trials should be scientifically sound with favorable risk-benefit ratio
3. Rights and welfare: Rights, safety, and well-being of subjects take precedence over science and society
4. Available information: Trials should use available nonclinical and clinical information
5. Quality: Trials should be scientifically sound and described in clear, detailed protocol
6. Compliance: Trials should comply with approved protocol
7. Qualified personnel: Trials should be conducted by qualified individuals
8. Informed consent: Freely given informed consent should be obtained from each subject
9. Privacy: Confidentiality of subject records must be protected
10. Quality assurance: Systems with procedures ensuring quality of data generated
11. Investigational products: Manufactured, handled, and stored per GMP; used per approved protocol
12. Documentation: Documentation systems should allow accurate reporting, interpretation, and verification
13. Quality management: Sponsor should implement quality management system
Before trial initiation:
During trial:
After trial:
Qualifications:
Compliance:
Safety reporting:
Source documents:
Source data verification (SDV):
Good documentation practice:
Corrections to source:
Minimum retention:
Documents to retain:
Elements of informed consent:
Additional elements (when appropriate):
Documentation:
Vulnerable populations:
IRB composition:
IRB review criteria:
IRB review types:
Continuing review:
Documentation:
IND requirements:
IND amendments:
Safety reporting:
General investigational plan:
EU CTR 536/2014 (replaced Clinical Trials Directive 2001/20/EC)
Key requirements:
Timelines:
ALCOA-CCEA:
Additional:
MHRA (UK) data integrity guidance:
Common data integrity issues:
This reference provides comprehensive guidance for regulatory compliance in clinical reports and clinical trials, including HIPAA, FDA regulations, ICH-GCP, and EU requirements. Ensure all clinical documentation adheres to applicable regulations.